UNITED THERAPEUTICS Corp (UTHR)

↓ Download CSV

CIK 0001082554 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, UNITED THERAPEUTICS Corp reported revenue of $3.18B, up 10.6% from the prior year. The company was profitable, with a net margin of 41.9% and a gross margin of 87.9%. It held $7.88B in total assets against $783.80M in total liabilities.

Key ratios (FY2025)

87.9%
Gross margin
46.9%
Operating margin
41.9%
Net margin
18.8%
Return on equity
+10.6%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$3.18B$2.88B$2.33B$1.94B$1.69B$1.48B$1.45B$1.63B$1.73B$1.60B
Cost of Revenue$384.40M$309.70M$257.50M$151.60M$122.50M$108.10M$117.60M$198.70M$105.70M$72.70M
Gross Profit$2.80B$2.57B$2.07B$1.78B$1.56B$1.38B$1.33B
Operating Income$1.49B$1.38B$1.18B$979.70M$555.90M$593.60M-$187.60M$805.40M$814.90M$1.06B
Net Income$1.33B$1.20B$984.80M$727.30M$475.80M
EPS (Diluted)$27.86$24.64$19.81$15.00$10.06$11.54$-2.39$13.39$9.31$15.25
Total Assets$7.88B$7.36B$7.17B$6.04B$5.17B$4.62B$3.91B$3.40B$2.88B$2.33B
Total Liabilities$783.80M$920.00M$1.18B$1.25B$1.21B$1.22B$1.13B$593.20M$758.40M$463.40M
Shareholders' Equity$7.10B$6.44B$5.98B$4.80B$3.96B$3.40B$2.78B$2.79B$2.10B$1.85B
Cash & Equivalents$1.56B$1.70B$1.21B$961.20M$894.80M$738.70M$738.40M$669.20M$705.10M$1.02B
Operating Cash Flow$1.56B$1.33B$978.00M$802.50M$598.20M$755.70M-$206.60M$778.40M$474.20M$643.60M
Capital Expenditures$520.50M$246.50M$230.40M$138.80M$120.80M$59.30M$83.70M$184.40M$86.30M$38.00M
Shares Outstanding47.90M48.50M49.70M48.50M47.30M44.60M43.80M44.00M44.90M46.80M